Letter from the Editor

Dear Reader,

The EADV from 25–28 September 2024 in Amsterdam provided information about important trends in the management of inflammatory skin diseases. Overall, there was reason for optimism under dermatologists: (1) for psoriasis, atopic dermatitis, and hidradenitis suppurativa, new treatments and important data from long-term studies were presented; and (2) new treatments are on the horizon for diseases with, until now, no effective treatments.

Atopic dermatitis

Temtokibart (IL-22RA inhibitor) and the PDE4 inhibitor orismilast were new kids on the block. Furthermore, insights from the “Scars of Life” project into the cumulative life impairment of atopic dermatitis. And 3-year efficacy results of lebrikizumab (IL-13 inhibitor).

Psoriasis

Imsidolimab, an IL-36 receptor antagonist, showed its efficacy in two phase 3 trials. In this report, you will also find a summary of a presentation on artificial intelligence in the management of psoriasis. Is AI-driven diagnosis of psoriasis possible? Which digital tools may assist the dermatologist in early diagnosis and the management of the disease?

Hidradenitis suppurativa

Izokibep, a new anti-IL-17 antibody was reported to be effective in this disease, which can be devastating to quality of life. Semaglutide, a GLP-1 agonist proved to be effective. Two-year data were presented on the treatment with bimekizumab.

New opportunities for diseases with limited therapeutic options so far

Nemolizumab, a  JAK1 inhibitor, proved to be effective in prurigo nodularis. Deucravacitinib was effective in lichen planopilaris. Deglocitinib cream, a pan-JAK inhibitor, improved hand eczema. Deuruxolitunib, a JAK1 and 2 inhibitor, was effective in alopecia areata. Ruxolitinib (JAK1 and 2 inhibitor) prolonged facial repigmentation in patients with vitiligo.

Optimism is justified following a visit to the EADV in Amsterdam. Treatment opportunities arise where dermatologists had little to offer in the past to patients who suffer from chronic persisting inflammatory skin diseases.

Best regards,

Peter CM van de Kerkhof

Biography

Peter C.M. van de Kerkhof is emeritus Professor of Dermatology and immediate past chairman of the Department of Dermatology of Radboud University Nijmegen. He is currently the coordinating Medical Officer of the International Psoriasis Council and chair of the scientific advisory board of the Dutch burn association. He has been working for many years on the pathogenesis and treatment of psoriasis. He has published more than 700 publications in peer-reviewed journals and has given many presentations on invitation at international conferences. He has served as president of the ESDR, EDF, and the International Psoriasis Council, and was a board member of various international societies. Current interests are pathogenesis and development of biomarkers for psoriasis; real clinical practice research; and personalised medicine.

Conflict of Interest Statement:Consultancy services for: Celgene, Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma,Sandoz, Mitsubishi Tanabe, Sandoz, Bristol Meyer Squibb, UCB, Dermavant.Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO Pharma, Sandoz, Bristol Meyer Squibb.



Posted on 6 November 20246 November 2024